Amgen (AMGN) Change in Account Payables (2009 - 2026)

Amgen (AMGN) has reported Change in Account Payables for 18 consecutive years, with $571.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables rose 14.89% year-over-year to $571.0 million; the TTM figure through Mar 2026 stood at $502.0 million (down 36.13% YoY), while the FY2025 annual figure was $428.0 million, up 37.18% from the prior year.
• Change in Account Payables came in at $571.0 million for Q1 2026 at Amgen, up from -$484.0 million in the prior quarter.
• The five-year high for Change in Account Payables was $643.0 million in Q2 2024, with the low at -$484.0 million in Q4 2025.
• Average Change in Account Payables over 5 years is $62.5 million, with a median of -$44.0 million recorded in 2022.
• Across the five-year window, Change in Account Payables sank 702.38% in 2023 and surged 2060.87% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $296.0 million in 2022, then plunged by 163.18% to -$187.0 million in 2023, then fell by 24.06% to -$232.0 million in 2024, then sank by 108.62% to -$484.0 million in 2025, then jumped by 217.98% to $571.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $571.0 million, -$484.0 million, and -$174.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.